Project/Area Number |
09470244
|
Research Category |
Grant-in-Aid for Scientific Research (B).
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | FUKUSHIMA MEDICAL UNIVERSITY (1999-2000) Gunma University (1997-1998) |
Principal Investigator |
TAKENOSHITA Seiichi Fukushima Medical University, School of Medicine, Professor, 医学部, 教授 (10167489)
|
Co-Investigator(Kenkyū-buntansha) |
SHIMURA Tatsuo Gunma Univeristy, School of Medicine, Assistant, 医学部, 助手 (00282393)
ASAO Takayuki Gunma University, School of Medicine, Assistant Professor, 医学部, 助教授 (40212469)
MIYAZONO Kouhei Tokyo University, Graduate School of Medicine, Professor, 大学院・医学系研究科, 教授 (90209908)
|
Project Period (FY) |
1997 – 2000
|
Project Status |
Completed (Fiscal Year 2000)
|
Budget Amount *help |
¥15,200,000 (Direct Cost: ¥15,200,000)
Fiscal Year 2000: ¥100,000 (Direct Cost: ¥100,000)
Fiscal Year 1999: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1998: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1997: ¥13,600,000 (Direct Cost: ¥13,600,000)
|
Keywords | TGF-β / Smad / Tumor suppressor gene / 増殖因子 / 遺伝子診断 |
Research Abstract |
The structure of objective genes on the human genome is essential for cancer related gene research grounded in DNA in clinical cancer studies. Since 1997, our research group efforts have : focused on structure decisions of MAD related genes and performed functional analysis to clarify TGF-13 signaling pathways and relation to cancer ; selected the TGF-β RII, Smad2, Smad3, Smad6, Smad7 ; examined all manner of cancer tissue gene abnormalities ; and reported those findings. Currently, the project is summarized as below. 1. Presently, the following are registered to EMBL/GenBanK (Data Libraries under Accession Nos.) Smad2 : U78726 to U78733 Smad3 : AF025293 to AF025300, AB004922 to AB004930 Smad4 : (promoter) : U44378 Smad6 : AF041062 to AF041065 Smad7 : AF026556 to AF026559 2. Among TGF-β signaling pathways analyzed here, confirmed gene mutations in human cancer tissue are Smad4, Smad2, TGF-β RII, and RI only. There are no abnormalities in Smad3, Smad6, and Smad7.
|